Novavax sees weak Covid vaccine sales

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi. Shares of the U.S. biotech firm fell 3% to $8.73.
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals and a pipeline of new vaccines it's now evaluating for R&D.
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Novavax falls after guidance cut on lower vaccine sales
Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its COVID-19 vaccine Nuvaxovid. Read more here.
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccine
The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.
Trump Taps Vaccine Skeptic RFK Jr. to Lead HHS. Moderna, Novavax Stock Slide.
Donald Trump nominated Robert F. Kennedy Jr., a vaccine skeptic and harsh critic of federal health agencies, to be his ...
Vaccine maker stocks fall as Trump chooses RFK Jr. to lead HHS
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
KSL3d
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Health Stocks Slide as Trump Picks Vaccine Skeptic Kennedy
Pharmaceutical stocks declined as President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr. to run the Department ...
Business Insider2d
Novavax Advances Vaccine Strategy Amid Financial Shifts
In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...
Novavax, UK terminate vaccine supply agreement
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...
BioPharma Dive3d
FDA lifts pause on Novavax flu vaccine trials
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 ...
Business Insider1d
Novavax price target lowered to $9 from $14 at TD Cowen
TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and ...